Activation of CAR has been shown to alleviate hepatic steatosis and fatty liver by inhibiting hepatic lipogenesis and inducing β-oxidation in HFD-fed and TCPOBOP-treated mice [115,126]. This evidence concerns the gene NR1I3 and Hepatic steatosis.